Il-33 secreting immunoresponsive cells and uses thereof
AssigneeMemorial Sloan Kettering Cancer Center
InventorsAnthony Daniyan, Renier J. Brentjens
Life of this patent
Estimating the term…
Abstract
The present disclosure provides methods and compositions for enhancing the immune response toward cancers and pathogens. It relates to an immunoresponsive cell comprising an antigen-recognizing receptor (e.g., a chimeric antigen receptor (CAR) or a T cell receptor (TCR)), and expressing increased level of IL-33. In certain embodiments, the engineered immunoresponsive cells are antigen-directed and have enhanced immune-activating properties.
Claims32
An immunoresponsive cell comprising:
- (a) an antigen-recognizing receptor that binds to an antigen, and
- (b) an exogenous IL-33 polypeptide or a fragment thereof.
An immunoresponsive cell comprising:
- (a) an antigen-recognizing receptor that binds to an antigen, and
- (b) a modified promoter at an endogenous IL-33 gene locus, wherein the modified promoter enhances gene expression of the endogenous IL-33 gene.
A nucleic acid composition comprising (a) a first nucleic acid sequence encoding an antigen-recognizing receptor and (b) a second nucleic acid sequence encoding an exogenous IL-33 polypeptide or a fragment thereof, each optionally operably linked to a promoter element.
Dependencies are inferred from the claim text.